Global Paclitaxel Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Paclitaxel Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".
Paclitaxel report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Paclitaxel market is projected to reach US$ 205.5 million in 2034, increasing from US$ 117.6 million in 2022, with the CAGR of 8.2% during the period of 2024 to 2034. Demand from Ovarian Cancer and Cervical Cancer are the major drivers for the industry.
North America and China are the largest producer of Paclitaxel, with a market share about 35% separately. Phyton, ScinoPharm, Huiang biopharma, Southpharma and Novasep are the top 5 manufacturers of industry, and they had more than 60% combined market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Paclitaxel market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Phyton
ScinoPharm
Novasep
Samyang
Polymed
TAPI (Teva)
Fresenius-kabi
Huiang biopharma
Southpharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology
Segment by Type
Natural Paclitaxel API
Semi-synthetic Paclitaxel API
Ovarian Cancer
Cervical Cancer
Breast Cancer
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Paclitaxel market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Paclitaxel, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Paclitaxel industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Paclitaxel in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Paclitaxel introduction, etc. Paclitaxel Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Paclitaxel market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Paclitaxel report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Paclitaxel market is projected to reach US$ 205.5 million in 2034, increasing from US$ 117.6 million in 2022, with the CAGR of 8.2% during the period of 2024 to 2034. Demand from Ovarian Cancer and Cervical Cancer are the major drivers for the industry.
North America and China are the largest producer of Paclitaxel, with a market share about 35% separately. Phyton, ScinoPharm, Huiang biopharma, Southpharma and Novasep are the top 5 manufacturers of industry, and they had more than 60% combined market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Paclitaxel market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Phyton
ScinoPharm
Novasep
Samyang
Polymed
TAPI (Teva)
Fresenius-kabi
Huiang biopharma
Southpharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology
Segment by Type
Natural Paclitaxel API
Semi-synthetic Paclitaxel API
Segment by Application
Ovarian Cancer
Cervical Cancer
Breast Cancer
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Paclitaxel market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Paclitaxel, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Paclitaxel industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Paclitaxel in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Paclitaxel introduction, etc. Paclitaxel Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Paclitaxel market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.